How do new antiplatelets reduce bleeding risk compared to aspirin?

How do new antiplatelets reduce bleeding risk compared to aspirin

Newer antiplatelet drugs work mainly by targeting specific platelet pathways that aspirin does not touch. They block receptors such as P2Y12 or glycoprotein IIb/IIIa, which aspirin does not affect. This selective action keeps the drug's effect on platelets more controlled and avoids the broad inhibition aspirin produces through irreversible COX-1 enzyme blocking.

Newer antiplatelet drugs reduce bleeding risk by using reversible binding mechanisms. Many bind reversibly to their receptors, so their effects fade once the drug leaves the body. Aspirin binds permanently to the COX-1 enzyme, disabling platelets for their entire life span. This reversibility helps doctors manage bleeding events more quickly if they occur.

Newer antiplatelets also have shorter half-lives than aspirin. Their drug effect stops after 2 hours or 4 hours for man-made inhibitors such as ticagrelor or cangrelor. Aspirin requires days to recover platelet function. This shorter duration allows clinical teams to plan procedures or respond to bleeding episodes without waiting days for platelet turnover.

What happens if you stop taking these drugs before a surgery

Newer antiplatelets show shorter recommended washout periods before operations. Surgeons require 3 to 5 days of interruption for drugs such as ticagrelor and prasugrel, rather than 7 to 10 days for aspirin. Washout guidelines issued by cardiology societies reflect these shorter times because of the drugs' reversible binding and shorter half-life.